Celltrion’s Truxima wins all the patent nullification trials in Korea

Celltrion announced the Intellectual Property Tribunal ruled nullification of the patent for the chronic lymphocytic leukemia(CLL) indication owned by Bio-Gen, which is related to the patent of Rituxan, the original product of Truxima, from the 7^th of February.

Celltrion had anticipatively filed a patent nullification trial over the Rituxan-related 5 indications registered at the Ministry of F...